Jasveen Sangha, the so-called “Ketamine Queen,” is preparing to plead guilty in the drug case linked to Matthew Perry’s fatal overdose, exposing Hollywood’s hidden network of illicit celebrity suppliers.
At a Glance
- Jasveen Sangha will plead guilty to supplying Matthew Perry with ketamine.
- She is the final defendant in a five-person case.
- The case highlights risks of unsupervised ketamine use for depression.
- Prosecutors are pushing for tighter drug regulations in response.
Celebrity Drug Scandal Unveiled
Hollywood is once again under the microscope as Jasveen Sangha, widely known as the “Ketamine Queen,” prepares to plead guilty in a federal case tied to the death of actor Matthew Perry. Her role in delivering the fatal dose underscores a broader, clandestine network catering to celebrities seeking access to restricted substances.
Perry, best known for his role in Friends, had been undergoing ketamine therapy to address depression. When legal access was curtailed by his physician, he turned to informal sources. Assistants and acquaintances facilitated these connections, eventually linking Perry to Sangha, who became his primary supplier. That pipeline ended in tragedy, adding his name to the long list of Hollywood figures lost to substance-related causes.
Watch now: ‘Ketamine Queen’ set to plead guilty in Matthew Perry case
Legal Ramifications and Investigation
Federal investigators spent months dismantling the supply chain that delivered ketamine to Perry. Sangha is the last of five defendants, and her guilty plea signals the end of a case that has laid bare the ease with which controlled substances can infiltrate celebrity circles.
Prosecutors contend that these networks are both highly organized and alarmingly accessible, posing dangers not just to celebrities but to others who emulate them.
The proceedings have amplified concerns about the regulation of ketamine, which has gained traction as an off-label treatment for mental health issues. While legally prescribed in controlled clinical settings, its misuse in unsupervised environments carries severe risks. The Perry case has become a cautionary tale, echoing previous Hollywood tragedies where fame offered no shield against addiction.
Implications for Mental Health and Drug Policy
The fallout from Sangha’s plea may stretch far beyond this single case. For Perry’s family, the legal resolution may provide closure. For policymakers, the case adds urgency to ongoing debates about how to regulate ketamine and other experimental treatments used for depression. Stricter oversight of prescriptions, tighter monitoring of celebrity medical care, and enhanced penalties for illegal suppliers are among the measures being discussed.
Hollywood, meanwhile, faces renewed scrutiny over its culture of accessibility to dangerous substances. With public attention fixed on the case, advocates argue that it highlights the delicate balance between expanding access to mental health treatments and preventing abuse. As Sangha awaits sentencing, the industry is left to reckon with the stark reminder that behind the glamour lies a vulnerability that fame cannot erase.
Sources
Matthew Perry and the Hollywood Drug Network Exposed by His Death
Jasveen Sangha, Known as ‘Ketamine Queen,’ Accused of Selling Matthew Perry Fatal Dose
‘Ketamine Queen’ Accused of Selling Fatal Dose to Matthew Perry
